glp 1 agonist in heart failure GLP-1 receptor agonists and myocardial metabolism atrial fibrillation Early trials of GLP-1 based

The LEADER CVOT trial found a higher incidence of DR-associated events in a group treated with liraglutide compared with placebo

Due to massive and persistent cultural and patient resistance and restrictive regulations, opioid-based OUD treatments like methadone and buprenorphine are used by a small fraction of people who could benefit from them

Wegovy injection is approved to help adults and children aged 12 years and older with obesity or some adults with excess weight (overweight), who also have weight-related medical problems, to lose weight and keep the weight off, in addition to diet and exercise

GLP-1 Receptor Agonist Market Segmentation Analysis By Product By product, the semaglutide segment accounted for a share of 51.23% in 2025, owing to its broad regulatory approvals across type 2 diabetes and obesity and proven cardiovascular risk reduction benefits

These developments favor therapeutic modalities, such as peptides, that can be mechanistically linked to disease pathways and monitored through pharmacodynamic readouts

The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials